🇺🇸 FDA
Patent

US 12043610

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

granted A61KA61K9/50A61P

Quick answer

US patent 12043610 (Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K9/50, A61P, A61P13/12, A61P25/28